Nomura/Instinet Reiterates Reduce On Alnylam Pharmaceuticals (ALNY) Ahead Of ENVISION Phase 3 Results
Go back to Nomura/Instinet Reiterates Reduce On Alnylam Pharmaceuticals (ALNY) Ahead Of ENVISION Phase 3 Results| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 242.61 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $242.61 | 52 Week High | $109.10 | |||
| Open | $242.61 | 52 Week Low | $31.38 | |||
| Day High | $242.61 | P/E | N/A | |||
| Day Low | $242.61 | EPS | $-1.45 | |||
| Volume | 874 | |||||
